Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hammond, M. E. H.; Hayes, D. F.; Dowsett, M.; Allred, D. C.; Hagerty, K. L.; Badve, S.; Fitzgibbons, P. L.; Francis, G.; Goldstein, N. S.; Hayes, M.; Hicks, D. G.; Lester, S.; Love, R.; Mangu, P. B.; McShane, L.; Miller, K.; Osbourne, C. K.; Paik, S.; Permutter, J.; Rhodes, A.; Sasano, H.; Schwartz, J. N.; Sweep, F. C.; Taube, S.; Torlakovic, E. E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R. B. ... view all 32 authors View less authors (2010)
Publisher: College of American Pathologists
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: skin and connective tissue diseases
Purpose: To develop a guideline to improve the\ud accuracy of immunohistochemical (IHC) estrogen receptor\ud (ER) and progesterone receptor (PgR) testing in breast\ud cancer and the utility of these receptors as predictive\ud markers.\ud Methods: The American Society of Clinical Oncology\ud and the College of American Pathologists convened an\ud international Expert Panel that conducted a systematic\ud review and evaluation of the literature in partnership with\ud Cancer Care Ontario and developed recommendations for\ud optimal IHC ER/PgR testing performance.\ud Results: Up to 20% of current IHC determinations of\ud ER and PgR testing worldwide may be inaccurate (false\ud negative or false positive). Most of the issues with testing\ud have occurred because of variation in preanalytic\ud variables, thresholds for positivity, and interpretation\ud criteria.\ud Recommendations: The Panel recommends that ER and\ud PgR status be determined on all invasive breast cancers and\ud breast cancer recurrences. A testing algorithm that relies\ud on accurate, reproducible assay performance is proposed.\ud Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered\ud positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.(Arch Pathol Lab Med. 2010;134:907–922)
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
    • 2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43, 2007
    • 3. Fitzgibbons PL, Murphy DA, Hammond MEH, et al: Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (in press)
    • 4. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716-721, 1985
    • 5. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996
    • 6. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474- 1481, 1999
    • 7. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000
    • 8. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11:419-429, 2002
    • 9. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006
    • 10. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004
    • 11. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
    • 12. Badve SS, Baehner FL, Gray RP, et al: Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26:2473-2481, 2008
    • 13. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007
    • 14. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26:1404-1410, 2008
    • 15. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006
    • 16. Phillips T, Murray G, Wakamiya K, et al: Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 15: 325-331, 2007
    • 17. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 26:1059-1065, 2008
    • 18. McGuire W, Carbone PP, Sears ME, et al: Estrogen receptors in human breast cancer, in McGuire WL, Carbone PP, Vollmer EP (eds): Estrogen Receptors in Human Breast Cancer. New York, NY, Raven Press, 1975, pp 1-7
    • 19. Osborne CK, Yochmowitz MG, Knight WA 3rd, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
    • 20. Knight WA 3rd, Osborne CK, McGuire WL: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9:361-368, 1980
    • 21. Cowen PN, Teasdale J, Jackson P, et al: Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay. Histopathology 17:319-325, 1990
    • 22. Stendahl M, Ryden L, Nordenskjold B, et al: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12:4614-4618, 2006
    • 23. Lockwood CA, Ricciardelli C, Raymond WA, et al: A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 84:203-208, 1999
    • 24. Esteban JM, Ahn C, Battifora H, et al: Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance. J Cell Biochem Suppl 19:138-145, 1994
    • 25. Yamashita H, Yando Y, Nishio M, et al: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74-83, 2006
    • 26. Jalava P, Kuopio T, Huovinen R, et al: Immunohistochemical staining of estrogen and progesterone receptors: Aspects for evaluating positivity and defining the cutpoints. Anticancer Res 25:2535-2542, 2005
    • 27. Ogawa Y, Moriya T, Kato Y, et al: Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cutoff point as the predictor for endocrine therapy. Breast Cancer 11:267-275, 2004
    • 28. Gown AM: Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol 121:172-174, 2004
    • 29. Nenci I, Beccati MD, Piffanelli A, et al: Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. J Steroid Biochem 7:505-510, 1976
    • 30. Diaz LK, Sneige N: Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10- 19, 2005
    • 31. Yaziji H, Taylor CR, Goldstein NS, et al: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16:513-520, 2008
    • 32. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92, 2003
    • 33. Taylor CR, Levenson RM: Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment II. Histopathology 49:411-424, 2006
    • 34. Gutman S: Regulatory issues in tumor marker development. Semin Oncol 29:294-300, 2002 Kenneth J. Bloom, MD Patrick Roche, PhD David L. Rimm, MD, PhD Hadi Yaziji, MD Richard Bender, MD Roseanne Welcher . Analytic specificity. Ability of a measurement procedure to measure solely the measurand/analyte.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article